Vital Therapies (NSDQ:VTL) said today that it inked a deal to swap shares with Germany-based Immunic, transitioning its efforts to focus on Immunic’s pipeline of drugs for chronic inflammatory and autoimmune diseases. Once the deal is closed, Vital Therapies plans to operate under the name Immunic and trade on the Nasdaq market. Get the full story […]
Vital Therapies
Vital Therapies reduces board size, looks to explore sale or merger
Vital Therapies (NSDQ:VTL) said yesterday that it reduced its board size from nine to four, and that it has begun to explore ‘strategic opportunities’ including a possible sale or merger of the company. The San Diego-based company said it retained Ladenburg Thalmann & Co. as its strategic financial advisor to assist in “the review of the […]
Vital Therapies to lay off 88% of workforce
Vital Therapies (NSDQ:VTL) is looking to lay off 88% of its employees, according to recently posed SEC filings. The move comes shortly after the San Diego-based company announced that its ELAD cell-based liver failure treatment failed to meet its endpoints in a pivotal clinical trial and saw its stock price drop 91.3%. Vital Therapies said it […]
Shareholders gut stock after Vital Therapies bails on Elad after failed trial
Vital Therapies (NSDQ:VTL) saw share price drop 91.3% this week after the company announced that the leading clinical trial of its ELAD cell-based therapy for treating liver failure failed to meet its primary and secondary endpoints and that it was “ceasing any further development” of the product. The San Diego-based company’s ELAD cell-based therapy was intended […]
Vital Therapies announces $30m follow-on offering
Vital Therapies (NSDQ:VTL) said today it is planning a $30 million follow-on stock offering to support its ELAD cell-based therapy system. The offering will include a 30-day underwriters option for an additional $4.5 million in shares, the San Diego, Calif.-based company said. The company is developing a cell-based therapy targeting the treatment of acute liver […]
Vital Therapies inks plan for new phase 3 Elad trial
Vital Therapies (NSDQ:VTL) outlined plans for a possible new phase 3 clinical trial to test its Elad treatment for liver failure in patients with alcohol-induced liver decompensation, according to an SEC filing posted yesterday. The company is developing a cell-based therapy targeting the treatment of acute liver failure, using a cartridge system designed to produce cells that […]
Vital Therapies to lay off 32, slash expenses, eyes clinical reboot
Vital Therapies (NSDQ:VTL) yesterday said it plans to lay of 32 employees, or about 30% of its workforce, and slash expenses as it looks to reboot its clinical program after the failure its Elad device in a trial last month. San Diego-based Vital Therapies halted a Phase III clinical trial of the Elad cell-based treatment for liver failure after […]
Vital Therapies trial fails to meet endpoints
Vital Therapies (NSDQ:VTL) said today that the Phase III clinical trial of its Elad cell-based therapy treatment for liver failure did not meet primary or secondary endpoints and the company is shutting down 2 other clinical studies of the device. The randomized, controlled, 203-patient trial examined the efficacy of the cell-based therapy in treating subjects with alcohol-induced […]
Vital Therapies prices offering
Vital Therapies looks to tap the market for $46M more
Vital Therapies (NSDQ:VTL) registered a $46 million public stock offering for its technique for the regeneration of liver tissue.
